GENE ONLINE|News &
Opinion
Blog

Deals
FDA Accepts Opdivo, Cabometyx Combo’s Priority Review Applications
2020-10-21
Cambridge Startup’s Take Two at Public Debut is Off to a Slow Start
2020-10-18
Eli Lilly Intends to Disarm Axonal Degeneration with Newest Acquisition
2020-10-17
With Two New Buyouts, 10X Genomics Places Bet on Emerging In Situ Field
2020-10-09
Boston Biotech, Alivio Receives Substantial Grant from U.S. DoD, a Second in Two Years
2020-10-08
Why is Bristol Myers Squibb Investing $13.1 Billion in MyoKardia?
2020-10-06
Chinook Therapeutics Completes Merger with Aduro BioTech Inc.
2020-10-05
Pfizer Strengthens Immuno-Oncology Portfolio with $200 Million Investment in Chinese Startup
2020-10-03
Dewpoint Snags Successful Series B to Target Lesser Known Cellular Compartments
2020-10-02
AI Powered Startup XtalPi Announces 300 Million Series C Funding
2020-09-30
Potential Treatment for Osteogenesis Imperfecta Receives FDA’s “Rare Pediatric Disease Designation”
2020-09-27
Investors Back Seattle-Based Startup’s Novel Immuno-Oncology Program Targeting Solid Tumors
2020-09-26
Roche Invests €380 Million on Inflammatory Disease Focusing Irish Biotech
2020-09-24
Magic Mushrooms Have the Potential as Depression Therapy?Compass Pathways Filing for IPO
2020-09-20
Illumina Advances Talks to Acquire Healthcare Start-up Grail
2020-09-16
1 40 41 42 43 44 47
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top